Replies to post #226 on Medicure Inc (MCUJF)

[SevenTenEleven]

MCUJ - Recent clinical data from Europe may suggest AGGRASTAT may have advantages over the competition. Safety and cost benefits.

Will be interesting to see if/how Medicure addresses the most recent data with the FDA.

Market is about $1B in sales, just in US, for products used in the therapeutic space where AGGRASTAT is indicated, and where it may have a further role.

[SevenTenEleven]

MCUJ - Nibbles on the ask continue. Looking for another day of breakout volume/accumulation. Buy on the dips.